Published in Mol Ther on August 30, 2005
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2008) 1.98
Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol (2007) 1.71
Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2011) 1.66
Biology of angiogenesis and invasion in glioma. Neurotherapeutics (2009) 1.61
Tumor endothelial cells. Cold Spring Harb Perspect Med (2012) 1.39
Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med (2007) 1.33
Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther (2010) 1.18
Stem cells and cell therapy approaches in lung biology and diseases. Transl Res (2010) 1.08
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A (2006) 1.05
High-resolution in-vivo analysis of normal brain response to cranial irradiation. PLoS One (2012) 1.00
Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res (2010) 0.93
Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes. Cancer Microenviron (2012) 0.88
Concise review: Vascular stem cells and tumor angiogenesis. Stem Cells (2011) 0.87
Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I. Am J Pathol (2007) 0.86
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer (2010) 0.86
Clinical implications of skeletal muscle blood-oxygenation-level-dependent (BOLD) MRI. MAGMA (2012) 0.85
Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett (2012) 0.84
Secretion of SDF-1alpha by bone marrow-derived stromal cells enhances skin wound healing of C57BL/6 mice exposed to ionizing radiation. J Cell Mol Med (2009) 0.81
Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. Semin Radiat Oncol (2013) 0.81
A novel high-resolution in vivo imaging technique to study the dynamic response of intracranial structures to tumor growth and therapeutics. J Vis Exp (2013) 0.80
Mesenchymal stem cells and their conditioned medium improve integration of purified induced pluripotent stem cell-derived cardiomyocyte clusters into myocardial tissue. Stem Cells Dev (2014) 0.78
Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog (2016) 0.75
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 1.78
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol (2008) 1.47
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47
Emerging functions of microRNAs in glioblastoma. J Neurooncol (2009) 1.44
microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle (2010) 1.40
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 1.26
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2009) 1.16
The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther (2002) 1.14
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets (2007) 1.11
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J Theor Biol (2009) 1.10
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology (2002) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. Tissue Eng Part C Methods (2009) 1.08
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther (2011) 1.05
MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia (2002) 1.03
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
In-training factors predictive of choosing and sustaining a productive academic career path in neurological surgery. Neurosurgery (2012) 1.03
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res (2011) 1.02
Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther (2004) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res (2013) 0.99
Lack of epidural pressure change with neck flexion in a patient with Hirayama disease: case report. Neurosurgery (2009) 0.99
Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med (2003) 0.99
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr (2012) 0.99
Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98
C2/C3 pathologic fractures from polyostotic fibrous dysplasia of the cervical spine treated with percutaneous vertebroplasty. Eur Spine J (2007) 0.97
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res (2003) 0.97
Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. Cancer Res (2012) 0.96
A retrospective cohort-matched comparison of conscious sedation versus general anesthesia for supratentorial glioma resection. Clinical article. J Neurosurg (2010) 0.96
The status of gene therapy for brain tumors. Expert Opin Biol Ther (2007) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer (2002) 0.93
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res (2012) 0.92
Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther (2009) 0.91
Functional response of tumor vasculature to PaCO2: determination of total and microvascular blood volume by MRI. Neoplasia (2003) 0.91
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther (2002) 0.91
Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther (2007) 0.90
Clinical and economic outcomes of low-field intraoperative MRI-guided tumor resection neurosurgery. J Magn Reson Imaging (2011) 0.89
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg (2011) 0.87
Potential role of miRNAs and their inhibitors in glioma treatment. Expert Rev Anticancer Ther (2010) 0.86
The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol (2004) 0.86
Spinal angiography and epidural venography in juvenile muscular atrophy of the distal arm "Hirayama disease". Muscle Nerve (2009) 0.86
Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology (2012) 0.86
The Gs-linked receptor GPR3 inhibits the proliferation of cerebellar granule cells during postnatal development. PLoS One (2009) 0.86
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Adv Virol (2011) 0.85
Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett (2012) 0.84
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology (2012) 0.84
Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. Mol Ther (2008) 0.83
Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther (2003) 0.83
Extent of resection. J Neurosurg (2011) 0.82
Reconstruction of Rare Skull Metastases Using Free Latissimus Dorsi Flap and the Role of Preoperative Embolization in Hypervascular Skull Tumors. J Craniofac Surg (2015) 0.82
DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res (2013) 0.82
Finding drugs against CD133+ glioma subpopulations. J Neurosurg (2010) 0.82
Quantitative analysis of surgical exposure and maneuverability associated with the endoscope and the microscope in the retrosigmoid and various posterior petrosectomy approaches to the petroclival region using computer tomograpy-based frameless stereotaxy. A cadaveric study. Clin Neurol Neurosurg (2012) 0.81
A viral strategy to ambush tumors. Nat Med (2011) 0.81
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology (2013) 0.81
Gene expression profiling of the anti-glioma effect of Cilengitide. Springerplus (2013) 0.81
Gene- and viral-based therapies for brain tumors. Neurotherapeutics (2009) 0.81
The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol (2012) 0.80
"Infectious" optimism for treatment of hepatocellular carcinoma. Mol Ther (2013) 0.80
Editorial: dural tail sign. J Neurosurg (2012) 0.80
Methylation markers of malignant potential in meningiomas. J Neurosurg (2013) 0.80
Oncolytic virotherapy for gliomas: steps toward the future. CNS Oncol (2013) 0.80
ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression. Mol Ther (2009) 0.80
Being old is no fun: treatment of glioblastoma multiforme in the elderly. J Neurosurg (2008) 0.79
Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol (2013) 0.79
Gene therapy for glioblastoma. Neurosurg Focus (2006) 0.79
Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. Mol Ther (2009) 0.79
Low Karnofsky Performance Scale score and glioblastoma multiforme. J Neurosurg (2011) 0.78
Intraoperative MRI (ioMRI) in the setting of awake craniotomies for supratentorial glioma resection. Acta Neurochir Suppl (2011) 0.78
The many functions of microRNAs in glioblastoma. World Neurosurg (2010) 0.78
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Mol Ther Nucleic Acids (2013) 0.78
Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature. J Neurosurg (2002) 0.78